Lindus Health Secures $55 Million to Revolutionize Clinical Trial Industry

London, January 22, 2025 - Lindus Health, a four-year-old startup backed by Peter Thiel, has raised a $55 million Series B round to address the inefficiencies of the clinical trial industry. The funding will accelerate Lindus's global expansion and enhance its AI-driven platform for end-to-end clinical trial management.

AI Advancements Drive Demand

Artificial intelligence (AI) is transforming drug discovery and development, increasing the need for a streamlined clinical trial process to bring new therapies to market faster. Lindus Health's platform combines automation and machine learning to expedite trial design, patient recruitment, and data collection.

Empowering Biotech Companies

By streamlining clinical trials, Lindus empowers biotech companies to test and iterate hypotheses more efficiently and safely. The platform includes a comprehensive suite of services, including staff management, regulatory support, and data analysis.

Market Opportunity

The clinical research organization (CRO) market is valued at $82 billion and projected to reach $130 billion by the end of the decade. Lindus's "anti-CRO" approach challenges the traditional industry model, offering a cost-effective and agile solution.

AI in Clinical Trials

The rise of AI is unlocking new possibilities in clinical trial technology. Lindus uses machine learning to generate initial trial protocols, reducing labor-intensive tasks. The platform also incorporates real-time data analysis to improve patient outcomes.

Series B Funding

Lindus Health's Series B round was led by Balderton Capital, with participation from Creandum, Firstminute, Seedcamp, and Visionaries. The funding will fuel Lindus's expansion in the U.S. and Europe, as well as its investment in AI and third-party integrations.

"We believe AI has the potential to revolutionize clinical trials," said Meri Beckwith, co-founder of Lindus Health. "We are dedicated to building a platform that accelerates drug development and improves patient outcomes."